Wellspect HealthCare Secures Medicare Reimbursement for Surity Urinary Management Portfolio
Event summary
- Wellspect HealthCare's Surity portfolio, including the Surity Urinary Management System and External Catheters, now eligible for Medicare reimbursement for eligible beneficiaries with permanent urinary incontinence.
- HCPCS codes A6590 and E2001 verified for reimbursement access.
- Surity portfolio launched in the U.S. in August 2026, becoming one of the most searched external catheter brands on Google.
- Wellspect HealthCare is a subsidiary of Dentsply Sirona (NASDAQ: XRAY).
The big picture
Wellspect HealthCare's Medicare reimbursement milestone for the Surity portfolio addresses a critical need for over 13 million people in the U.S. living with urinary incontinence. This strategic move aligns with broader industry trends toward non-invasive, patient-centric solutions in continence care. The reimbursement access could significantly reduce barriers to care, potentially expanding Wellspect's market reach and reinforcing its position as a leader in innovative medical devices for bladder and bowel dysfunction.
What we're watching
- Market Penetration
- How the Medicare reimbursement will affect adoption rates of the Surity portfolio among eligible beneficiaries.
- Competitive Dynamics
- Whether Wellspect HealthCare can sustain its market position with the Surity portfolio against existing competitors in the urinary management space.
- Regulatory Compliance
- The pace at which Wellspect HealthCare can navigate additional regulatory hurdles to expand reimbursement access in other markets.
Related topics